Tag: DB-1303
Accelerating the Development of Differentiated ADCs: BioNTech and DualityBio Form Global...
German-based BioNTech and Duality Biologics (Suzhou) Co, a Shanghai-based clinical-stage biotech company, have entered into exclusive license and collaboration agreements for the ongoing development manufacture and globally* commercialize two investigational antibody-drug conjugates (DB-1303 and DB-1311) directed against HER2.
FDA Grants Fast Track Designation to DB-1303 for the Treatment of...
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.
